In oncology, the balance between rapid innovation and patient safety is critical. The recent withdrawal of an accelerated approval cancer drug highlights the need for more stringent evidence and robust trial design to truly benefit patients.

In a recent case, an emergency physician’s strict adherence to snakebite treatment guidelines was scrutinized in court, illustrating the legal and medical ramifications of protocol-driven care in emergency medicine.

Recent findings presented at the ASA’s annual meeting spotlight the critical role of tranexamic acid in postpartum hemorrhage, underscoring a dose-response relationship that enhances antifibrinolysis, marking a significant advancement in obstetric care.

GLP-1 agonists are increasingly recognized for their dual benefits in type 2 diabetes management and cardiovascular risk reduction, offering a multifaceted approach to patient care in an expanding global market.

The Inflation Reduction Act’s out-of-pocket cap on Medicare Part D spending marks a pivotal shift in healthcare economics, potentially altering prescription drug cost dynamics for millions of enrollees. Physicians should be aware of these changes to better support and inform their patients navigating these new financial landscapes.

Metformin is emerging as a viable option for weight management in obese patients without diabetes, showing sustained weight loss effects and potential benefits in populations with prediabetes or undergoing antipsychotic treatment.